AstraZeneca Pharma India, the Indian subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, has decided to delist its scrip from the Bombay Stock Exchange, National Stock Exchange and Bangalore Stock Exchange.
Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?
Investors cheered a sharp decline in the Current Account Deficit, which stands at a 4 year low as exports picked up and gold imports reduced.
Compared to their Indian peers, MNCs have higher return ratios.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances